Fresenius SE & Co. KGaA (0OO9.L)

26,93 -0,77 (-2,78%) In data: 06:45PM BST. Mercato aperto.

Fresenius SE & Co. KGaA

Else-Kroener-Strasse 1
Bad Homburg vor der Höhe 61352
Germany
49 6172 6080
https://www.fresenius.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 193.865

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael Sen	CEO, President & Chairman of Management Board - Fresenius Management SE	4,09M	N/D	1968
Ms. Sara Lisa Hennicken	CFO & Member of the Management Board - Fresenius Management SE	1,55M	N/D	1980
Mr. Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	2M	N/D	N/D
Dr. Michael Sven Moser Ph.D.	Member of Management Board of Fresenius Management SE	1,2M	N/D	1978
Mr. Robert Moller	Member of the Management Board of Fresenius Management SE	1,15M	N/D	1971
Mr. Markus Georgi	Senior Vice President of Investor Relations	N/D	N/D	N/D
Matthias Link	Senior Vice President Corporate Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Governance aziendale

L'ISS Governance QualityScore di Fresenius SE & Co. KGaA al 1 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.